Last updated: September 7, 2026
Etrumadenant, also known as AB928, is an oral small-molecule antagonist of the adenosine A2A and A2B receptors. Arcus Biosciences developed the candidate for combination use in solid tumors, particularly non-small-cell lung cancer, pancreatic cancer, and colorectal cancer. Arcus discontinued further clinical development of etrumadenant, eliminating a near-term commercial launch case. Its base-case market value is therefore zero unless another sponsor revives the program or licenses the asset.
What is the current development status of etrumadenant?
Etrumadenant is no longer an active clinical development program in Arcus Biosciences' pipeline. Arcus' public disclosures identified the program as discontinued after clinical development failed to justify continued investment relative to other pipeline programs.[1,2]
| Item |
Status |
| Generic name |
Etrumadenant |
| Development code |
AB928 |
| Sponsor |
Arcus Biosciences |
| Pharmacology |
Dual adenosine A2A/A2B receptor antagonist |
| Dosage form |
Oral small molecule |
| Primary development area |
Oncology |
| Principal tumor areas |
NSCLC, pancreatic cancer, colorectal cancer |
| FDA approval |
None |
| FDA regulatory designation |
No publicly identified approval or active marketing application |
| Orange Book listing |
None |
| Current clinical status |
Discontinued |
| Commercial sales |
None |
Etrumadenant was designed to block adenosine-mediated immune suppression in the tumor microenvironment. A2A and A2B receptor signaling can inhibit antitumor immune activity and promote an immunosuppressive environment. Arcus tested the drug primarily in combination with immune checkpoint inhibitors and other immune-oncology agents.
Which clinical trials evaluated etrumadenant?
Etrumadenant entered several combination studies, but the program did not advance to a registrational filing.
Key clinical development programs
| Program |
Disease setting |
Principal combination strategy |
Development relevance |
| ARC-7 |
First-line metastatic NSCLC |
Etrumadenant with zimberelimab and domvanalimab |
Major test of the adenosine mechanism in lung cancer |
| ARC-6 |
Advanced pancreatic cancer |
Etrumadenant with immune-oncology agents and chemotherapy |
Test of immune modulation in a highly immunosuppressive tumor |
| ARC-8 |
Advanced colorectal cancer |
Etrumadenant-based combination therapy |
Evaluation in tumors with limited checkpoint-inhibitor sensitivity |
| Other early studies |
Advanced solid tumors |
Etrumadenant monotherapy or combinations |
Pharmacology, safety and dose selection |
ARC-7 was the most commercially important study because first-line metastatic NSCLC is a large market with established immunotherapy demand. The program tested whether adding etrumadenant could improve outcomes over immune checkpoint therapy alone or over other Arcus combinations.
ClinicalTrials.gov records show that etrumadenant was evaluated in interventional oncology studies, but there is no FDA-approved indication and no phase 3 filing program for the drug.[3]
Did etrumadenant demonstrate clinical efficacy?
Public disclosures did not establish a clinical benefit sufficient to support continued development. Arcus' decision to discontinue the program indicates that the company did not consider the available efficacy, development risk, or commercial opportunity adequate for further investment.
The principal development challenge was combination attribution. Etrumadenant was tested alongside other experimental agents, including zimberelimab and domvanalimab. If a combination produces a signal, separating the contribution of the adenosine antagonist from the checkpoint inhibitor or TIGIT-directed component is difficult. This increases trial complexity and weakens the standalone value of the asset.
The program also faced a competitive oncology environment in which treatment regimens must show a clear progression-free-survival or overall-survival advantage over established checkpoint-inhibitor standards. A biologically plausible mechanism was insufficient to support commercial progression without a measurable clinical signal.
When does etrumadenant lose exclusivity?
Etrumadenant has no approved-product exclusivity period because it has not received FDA approval. It therefore has no active new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or approved-label exclusivity under the Federal Food, Drug, and Cosmetic Act.
Patent protection is separate from regulatory exclusivity. Arcus and related entities filed patent applications covering adenosine receptor antagonists, including composition-of-matter, pharmaceutical-composition, and therapeutic-use claims. The effective expiration date varies by patent family, jurisdiction, patent-term adjustment, patent-term extension, terminal disclaimers, and the scope of surviving claims.
| Exclusivity category |
Etrumadenant status |
| FDA approval |
None |
| New chemical entity exclusivity |
None granted |
| Orphan-drug exclusivity |
None publicly identified |
| Pediatric exclusivity |
None |
| Orange Book patents |
None |
| Composition patents |
Publicly disclosed patent families exist |
| Method-of-use patents |
Publicly disclosed or potentially relevant |
| Patent-term extension |
Not applicable without an approved product |
| Commercial patent cliff |
No established commercial cliff |
Because the asset has no approved indication, there is no legally operative Orange Book patent-expiration date for generic applicants to challenge.
What patents protect etrumadenant?
The patent estate is expected to include several claim categories:
- Composition-of-matter claims covering substituted heterocyclic compounds that inhibit A2A and A2B receptors.
- Pharmaceutical-composition claims covering oral dosage forms and formulations.
- Method-of-treatment claims for cancer and other diseases involving adenosine signaling.
- Combination-treatment claims pairing etrumadenant with checkpoint inhibitors, chemotherapy, or other immuno-oncology agents.
- Use claims directed to selected tumor types or biomarker-defined patient groups.
The strongest potential protection would normally come from an issued composition-of-matter patent with a term extending into the late 2030s. Method-of-use and formulation claims would generally provide narrower protection and could be easier to design around.
No Orange Book listing exists because etrumadenant has not been approved. A future licensee would need to review the United States Patent and Trademark Office file histories and international national-phase records to determine which claims remain enforceable. Public pipeline disclosures alone do not establish a single definitive patent expiration date.
Are there Paragraph IV challenges to etrumadenant?
No Paragraph IV challenge is publicly relevant because etrumadenant has no FDA-approved reference listed drug and no Orange Book-listed patents.
A Paragraph IV certification applies to an abbreviated new drug application referencing an approved drug. Etrumadenant has not reached that stage. Any future generic challenge would require an FDA-approved reference product, an approved label, and listed patents. None currently exists.
The more immediate legal issue would be ownership, license scope, and patent validity if a sponsor sought to revive the program. Potential disputes could involve:
- Inventorship and assignment of the AB928 patent families.
- Rights retained by Arcus after discontinuation.
- Contractual rights held by AstraZeneca under the Arcus collaboration.
- Patent-term adjustment and terminal-disclaimer calculations.
- Claim scope for combination therapy and formulation patents.
What was the AstraZeneca licensing arrangement for etrumadenant?
Arcus and AstraZeneca entered a strategic oncology collaboration covering multiple Arcus programs, including etrumadenant and other immune-oncology assets. The transaction was reported as having a potential value of up to approximately $6.5 billion across the collaboration, including upfront consideration, equity investment, development payments, regulatory milestones, and commercial milestones.[4]
The agreement gave AstraZeneca rights and options across the Arcus oncology portfolio. Etrumadenant did not produce a marketed product or a disclosed commercial milestone stream. Arcus' discontinuation of the program materially reduced the practical value of the asset within that collaboration.
For a potential acquirer, the principal licensing questions are whether AstraZeneca retains any option, consent, reversion, or participation rights and whether the relevant patent families were assigned, jointly owned, or licensed on a program-by-program basis.
What is the FDA and Orange Book status of etrumadenant?
Etrumadenant has no FDA approval, no approved biologics license application, no approved new drug application, and no Orange Book entry. It is a small molecule, so the relevant future pathway would be an NDA rather than a biologics license application.
The regulatory path would require renewed clinical development, including:
- A clinical program demonstrating a clinically meaningful benefit.
- Adequate safety data for the intended treatment population.
- Manufacturing and quality controls for the drug substance and oral product.
- A final dose and combination regimen.
- A defined indication and labeling strategy.
No FDA approval timeline, PDUFA date, or regulatory exclusivity timeline exists.
How strong is the etrumadenant patent estate?
The patent estate has technical breadth but limited current commercial strength.
| Strength factor |
Assessment |
| Composition protection |
Potentially strong if valid claims remain in force |
| Formulation protection |
Secondary; likely narrower |
| Method-of-use protection |
Potentially useful but dependent on clinical label |
| Regulatory exclusivity |
None |
| Orange Book leverage |
None |
| Clinical validation |
Insufficient to support launch |
| Commercial readiness |
Low |
| Manufacturing barrier |
Moderate for a specialized small molecule, but not a proven barrier |
| Litigation leverage |
Limited without an approved product |
| Partnering value |
Dependent on clinical revival and rights clearance |
The most valuable asset would be a validated composition patent coupled with a demonstrated clinical benefit in a defined tumor type. Without clinical validation, the patent estate does not create a standalone commercial franchise.
What is the market projection for etrumadenant?
The base-case commercial forecast is zero product revenue. Arcus discontinued development, and no sponsor has publicly announced a registration plan or relaunch.
| Forecast period |
Base-case status |
Revenue outlook |
| 2025-2026 |
No active development or approval |
Zero |
| 2027-2028 |
No disclosed restart |
Zero |
| 2029-2030 |
No disclosed launch pathway |
Zero |
| Long-term upside case |
Acquisition, licensing and successful redevelopment |
Unquantified |
A revived program could target large markets, particularly first-line NSCLC. However, the commercial opportunity would be incremental to existing checkpoint-inhibitor regimens rather than a standalone market. Pricing would depend on whether etrumadenant is used as monotherapy, in a fixed combination, or as part of a multi-agent regimen.
The addressable market would be constrained by:
- Competition from pembrolizumab-based regimens.
- Numerous immune-oncology combinations.
- The need to demonstrate additive benefit.
- Combination-treatment pricing and reimbursement pressure.
- Clinical-trial costs in first-line cancer.
- Potential safety and tolerability issues from chronic adenosine-pathway blockade.
- Lack of an established biomarker strategy.
An acquisition would therefore be more likely to reflect option value than current revenue value. The asset could retain strategic relevance as a backup or combination component, but the discontinued development status sharply reduces its near-term valuation.
How does etrumadenant compare with competing adenosine-pathway drugs?
Etrumadenant was differentiated by dual A2A/A2B blockade and oral administration. Many competing programs focused on A2A alone or used a different approach to the adenosine pathway.
| Asset or approach |
Target |
Development position relative to etrumadenant |
| Etrumadenant |
A2A/A2B |
Discontinued by Arcus |
| Ciforadenant |
A2A |
Earlier clinical adenosine antagonist program |
| AZD4635 |
A2A |
Clinical adenosine-pathway competitor |
| Inupadenant |
A2A |
Clinical-stage A2A antagonist program |
| CD73 inhibitors |
Adenosine generation |
Alternative upstream strategy |
| CD39 inhibitors |
Extracellular ATP-to-adenosine pathway |
Alternative upstream strategy |
| Adenosine deaminase or pathway modifiers |
Adenosine metabolism |
Mechanistically distinct alternatives |
The dual-target approach offered broader pathway coverage but also increased the need to prove that A2B blockade contributed clinically meaningful benefit. No adenosine-pathway antagonist has established a broad commercial oncology franchise comparable to PD-1 or PD-L1 inhibitors.
What generic launch risks exist?
There is no immediate generic-launch risk because there is no approved reference product. The principal risk is instead asset obsolescence.
If the drug were revived, generic entry would depend on:
- The surviving composition-of-matter patent term.
- FDA approval of a reference product.
- Orange Book listing decisions.
- The scope of approved indications.
- Whether formulation and method patents are listed.
- Patent challenges under Paragraph IV.
- Potential design-around compounds.
A future generic manufacturer would likely challenge narrower method-of-use or formulation claims before challenging a strong composition patent. A composition patent covering the specific active molecule would present the largest barrier.
Key Takeaways
- Etrumadenant is an oral dual A2A/A2B adenosine receptor antagonist developed by Arcus Biosciences.
- The program was tested in NSCLC, pancreatic cancer, colorectal cancer, and other solid tumors.
- Arcus discontinued further development after the clinical package failed to support continued investment.
- Etrumadenant has no FDA approval, no Orange Book listing, and no regulatory exclusivity.
- No Paragraph IV challenge is currently relevant.
- Public patent families may provide composition, formulation, and method-of-use protection, but no single commercial patent-expiration date governs the asset.
- AstraZeneca's broader Arcus collaboration had reported potential value of up to approximately $6.5 billion, but etrumadenant did not produce commercial revenue.
- The base-case market forecast is zero through 2030.
- Any value now depends on a third-party revival, rights clearance, new clinical evidence, and successful combination development.
FAQs
Is etrumadenant still being developed?
No. Arcus Biosciences discontinued further clinical development of etrumadenant.
Is etrumadenant approved by the FDA?
No. Etrumadenant has no FDA approval, NDA approval, or approved oncology indication.
Does etrumadenant have an Orange Book patent?
No. There is no Orange Book listing because there is no approved reference product.
Could another company license etrumadenant?
Yes, but a transaction would require confirmation of patent ownership, AstraZeneca rights, clinical data access, manufacturing capability, and the commercial rationale for restarting development.
What cancer was etrumadenant intended to treat?
The principal development targets were metastatic NSCLC, pancreatic cancer, colorectal cancer, and other advanced solid tumors, generally in combination with immune checkpoint or other immune-oncology therapies.
References
-
Arcus Biosciences, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Arcus Biosciences, Inc. (2024). Corporate pipeline and clinical development updates. Arcus Biosciences.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov records for etrumadenant and AB928 clinical studies. ClinicalTrials.gov.
-
AstraZeneca. (2019). AstraZeneca and Arcus Biosciences enter strategic oncology collaboration. AstraZeneca corporate announcement.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
